Repligen corp stock.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ...Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset …Repligen Corp Bond (US:US759916AB50) has 3 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC) ...

Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.Get Repligen Corp (RGEN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The United States Marines traces its roots back to 1776, and it’s the oldest military institution in the country. When Marines earn distinction during their service, the Marine Corps recognizes this service with a variety of medals and ribb...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Stock Exchange NASDAQ Ticker Symbol RGEN Full Company Profile Financial Performance In 2022, Repligen's revenue was $801.54 million, an increase of …

Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Stock Exchange NASDAQ Ticker Symbol RGEN Full Company Profile Financial Performance In 2022, Repligen's revenue was $801.54 million, an increase of …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 47.0. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ...

Stock analysis for Repligen Corp (R2GE34:B3 Day) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Third quarter 2023 adjusted gross profit was $59.3 million, a 48% decrease year-over-year and nearly $60 million of lower revenue, and on a lower adjusted gross margin, which was 42% in the third ...As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Dec 4, 2023 · × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Within the last quarter, Repligen (NASDAQ:RGEN) has observed the following analyst ratings: According to 7 analyst offering 12-month price targets in the last …

Nov 3, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Repligen Corp. analyst ratings, historical stock prices, earnings estimates & actuals. RGEN updated stock price target summary.

Repligen Corp., which was founded by Alexander G., provides bioprocessing technologies and services utilized in producing biological drugs. ... With institutions owning 91% of its stock, it’s clear that Repligen is attracting some serious attention from experienced and savvy investors who see its potential for growth in the biotech sector ...Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Repligen - RGEN - Stock Price Today - Zacks Repligen (RGEN) (Delayed Data from NSDQ) $164.94 USD +7.69 (4.89%) Updated Dec 1, 2023 04:00 PM ET After-Market: $161.40 -3.54 (-2.15%) 7:58 PM ET...A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Dec 1, 2023 · View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...RGEN - Repligen Corp. - Stock screener for investors and traders, financial visualizations.RGEN: Repligen Corp Stock Price Quote - NASDAQ GS - Bloomberg Back Forward Markets Data Repligen Corp RGEN:US Nasdaq GS (USD) As of 12:00 AM …Oct 31, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ... Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.

Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%. Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise. Get the latest Repligen Corporation …Instagram:https://instagram. best stocks under 25 dollarsindependence financial advisorsvinfast stock nasdaqaitx news Stocks of Repligen Corp. saw a sharp rise in short interest on Nov 14, 2023 jumping by 10000.0 shares to 5.99 million. Data from Yahoo Finance shows that the short interest on Oct 12, 2023 was 5.98 million shares. A jump of 0.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just ... stocks overvaluedmojo sportsbook Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued. nasdaq mbly news Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%. Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.